# PhenoMX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phenomx

- Industry: Software
- Headquarters: Gyeonggi-do, South Korea
- Website: www.phenomx.co.kr
- Latest round: Series A (Dec 24, 2021)
- Investors on record: 6

## About

Based in South Korea, PhenoMX specializes in developing advanced health monitoring solutions that integrate biometric data with artificial intelligence to promote better health management.PhenoMX, founded in 2020 and headquartered in Gyeonggi-do, South Korea, develops innovative health monitoring platforms. The company was established by Girish Srinivasan, who has a background in technology and healthcare. PhenoMX participated in 4 funding deals, with the most recent deal occurring on December 24, 2021, during their SERIES A funding round.PhenoMX offers a range of advanced technological solutions designed primarily for the healthcare and wellness sectors. Their core product is a sophisticated health monitoring platform that integrates biometric data collection with artificial intelligence analytics to provide users with actionable insights regarding their health. This platform aims to enhance personal health management by addressing key challenges such as chronic disease monitoring and preventative health strategies. The end users include individual consumers seeking better health outcomes, healthcare providers leveraging the platform for patient management, and wellness organizations aiming to promote healthier lifestyles. The geographical markets for PhenoMX’s products extend beyond the domestic landscape, targeting regions such as North America and parts of Europe, where there is a growing demand for personalized health solutions.PhenoMX generates revenue through a subscription-based model that aligns with various user needs across its customer base. Clients typically engage with the company via direct-to-consumer channels, where individual users can subscribe to access the platform's features on a monthly or annual basis. There are also B2B partnerships established with healthcare providers, who may purchase bulk licenses for use in their practices. The pricing structure is designed to cater to different tiers of service, ensuring accessibility for a wide range of customers while also providing premium features for more intensive users. Flagship offerings may include specific modules tailored for chronic disease management or wellness tracking, which are instrumental in driving client retention and acquisition.PhenoMX is focusing on expanding its product line by designing new features for its health monitoring platform, with plans for a rollout by late 2023. The company aims to enter new markets, specifically in North America and Europe, by 2024. The funds raised in the SERIES A round, led by InterValue Partners and supported by BNK Venture Capital and KAIC, will be utilized to support these initiatives and enhance their technological capabilities.

## Funding rounds

- Series A, Dec 24, 2021 — BNK Venture Capital, InterValue Partners, Chung-Ang University KAIC
- Seed, May 1, 2021 — Korea Tech Incubator for Startup, Infobank
- Seed, Nov 27, 2020 — New Paradigm Investment

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Seed
- Korea Tech Incubator for Startup — Seed
- Infobank (https://capitalatlas.ai/funds/infobank) — Seed
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series A
- InterValue Partners (https://capitalatlas.ai/funds/intervalue-partners) — Series A
- Chung-Ang University KAIC — Series A